Merck & Co Inc (NYSE:MRK) – Merck Earnings Miss Estimates on Diabetes Drug Slump

February 05, 2014 at 07:22 AM EST

[at Bloomberg] – Merck & Co., the second-biggest U.S. drugmaker by sales, reported fourth-quarter profit that missed analysts’ estimates as sales of its top diabetes drug Januvia fell short. Earnings (MRK) excluding certain . . . → Read More: Merck & Co Inc (NYSE:MRK) – Merck Earnings Miss Estimates on Diabetes Drug Slump Similar Articles: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug after prior rejection Medtronic Inc. (NYSE:MDT) | Medtronic second-quarter earnings rise; top estimates Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise

Merck & Co Inc (NYSE:MRK) [at Bloomberg] – Merck & Co., the second-biggest U.S. drugmaker by sales, reported fourth-quarter profit that missed analysts’ estimates as sales of its top diabetes drug Januvia fell short. Earnings (MRK) excluding certain items were 88 cents a share, 1 cent below the average of 15 analysts’ estimates compiled by Bloomberg. Under new science head Roger Perlmutter, Merck has overhauled its research and development programs, shuttering some efforts and putting … [visit site to read more]